MCID: SBR004
MIFTS: 45

Seborrheic Dermatitis

Categories: Immune diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Seborrheic Dermatitis

MalaCards integrated aliases for Seborrheic Dermatitis:

Name: Seborrheic Dermatitis 11 28 53 14 16 71
Seborrhoeic Dermatitis 11 75 31
Dermatitis, Seborrheic 43
Seborrhoeic Eczema 11
Skin Seborrheic 11
Seborrhea 11

Classifications:



External Ids:

Disease Ontology 11 DOID:8741
ICD9CM 34 690.1
MeSH 43 D012628
NCIt 49 C111888
SNOMED-CT 68 156328004
ICD10 31 L21 L21.9
UMLS 71 C0036508

Summaries for Seborrheic Dermatitis

Disease Ontology: 11 A dermatitis that is an inflammatory skin condition resulting in flaky, white to yellowish scales on oily areas such as the scalp or inside the ear, which is caused due to a combination of an over production of skin oil and irritation from a yeast Malassezia furfur. The symptoms include itching, skin lesions and scales, redness, plaques and hair loss.

MalaCards based summary: Seborrheic Dermatitis, also known as seborrhoeic dermatitis, is related to seborrheic infantile dermatitis and keratosis, seborrheic. An important gene associated with Seborrheic Dermatitis is BTD (Biotinidase), and among its related pathways/superpathways are Innate Immune System and Innate Lymphoid Cells Differentiation. The drugs Ciclopirox and Salicylic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, ovary and spinal cord.

Wikipedia: 75 Seborrhoeic dermatitis, sometimes inaccurately referred to as seborrhoea, is a long-term skin disorder.... more...

Related Diseases for Seborrheic Dermatitis

Diseases in the Seborrheic Dermatitis family:

Seborrheic Infantile Dermatitis

Diseases related to Seborrheic Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 526)
# Related Disease Score Top Affiliating Genes
1 seborrheic infantile dermatitis 33.1 ZNF750 MPZL3 FLG
2 keratosis, seborrheic 31.6 CD1E CD1D CD1C CD1B CD1A
3 dermatitis 30.9 ZNF750 TNF SPINK5 LORICRIN FLG DSG1
4 exanthem 30.7 TNF CXCL8 CD4 CCR6
5 acne 30.6 TNF SHBG FLG DEFB4A CXCL8
6 dermatophytosis 30.6 TNF DEFB4A CD4 CCR6
7 skin atrophy 30.4 TNF LORICRIN FLG
8 tinea pedis 30.3 DEFB4A CD4 CCR6
9 blepharitis 30.3 TNF CXCL8 CD4 CCR6
10 geographic tongue 30.3 CD1E CD1B CD1A
11 alcohol use disorder 30.3 TNF CD4 CCR6
12 tinea corporis 30.3 FLG DEFB4A CD4
13 scabies 30.2 FLG CD4 CD1E CCR6
14 candidiasis 30.2 TNF DEFB4A CXCL8
15 skin sarcoidosis 30.2 TNF CD4 CCR6
16 oral candidiasis 30.2 DEFB4A CD4 CCR6
17 histoplasmosis 30.1 TNF CD4 CCR6
18 dermatitis, atopic 30.1 TNF SPINK5 LORICRIN FLG DEFB4A CXCL8
19 pyoderma 30.0 TNF DSG1 CXCL8 CCR6
20 psoriasis 30.0 TNF SPINK5 LORICRIN FLG DEFB4A CXCL8
21 pyoderma gangrenosum 30.0 TNF CXCL8 CCR6
22 peptic ulcer disease 30.0 TNF CXCL8 CCR6
23 pemphigoid 30.0 TNF DSG1 CXCL8
24 crohn's disease 30.0 TNF CXCL8 CD4 CCR6
25 mite infestation 29.9 FLG CD4 CD1E CD1B CD1A CCR6
26 folliculitis 29.9 TNF DEFB4A CD4 CD1E CD1B CD1A
27 viral infectious disease 29.8 TNF CXCL8 CD4 CCR6
28 celiac disease 1 29.8 TNF CXCL8 CD4 CCR6
29 eczema herpeticum 29.7 SPINK5 LORICRIN FLG DEFB4A CCR6
30 lichen planus 29.7 TNF FLG DSG1 DEFB4A CXCL8 CD1A
31 bullous pemphigoid 29.7 TNF DSG1 CXCL8
32 contact dermatitis 29.6 TNF SPINK5 LORICRIN FLG DEFB4A CXCL8
33 granuloma annulare 29.5 TNF CD4 CD1E CD1D CD1C CD1B
34 skin disease 28.8 TNF SPINK5 LORICRIN FLG DSG1 DEFB4A
35 seborrhea-like dermatitis with psoriasiform elements 11.5
36 garret tripp syndrome 11.2
37 neurodevelopmental disorder with epilepsy and hemochromatosis 11.1
38 chronic actinic dermatitis 11.1
39 acromegaloid changes, cutis verticis gyrata, and corneal leukoma 11.0
40 hyperandrogenism 11.0
41 psoriasis 1 10.6
42 psoriasis 2 10.6
43 psoriasis 7 10.6
44 psoriasis 11 10.6
45 psoriasis 13 10.6
46 trichohepatoenteric syndrome 1 10.5
47 rosacea 10.5
48 pityriasis versicolor 10.5
49 immune deficiency disease 10.4
50 fanconi anemia, complementation group e 10.4

Graphical network of the top 20 diseases related to Seborrheic Dermatitis:



Diseases related to Seborrheic Dermatitis

Symptoms & Phenotypes for Seborrheic Dermatitis

Drugs & Therapeutics for Seborrheic Dermatitis

Drugs for Seborrheic Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
2
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
3
Ketoconazole Approved, Investigational Phase 4 65277-42-1, 142128-57-2 47576 3823 638701
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
7
Isotretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4, 4759-48-2 5538 444795 5282379
8 Antirheumatic Agents Phase 4
9 Anti-Inflammatory Agents, Non-Steroidal Phase 4
10 Analgesics, Non-Narcotic Phase 4
11 Analgesics Phase 4
12 Keratolytic Agents Phase 4
13 Cyclooxygenase Inhibitors Phase 4
14
Salicylates Phase 4
15 Hormones Phase 4
16 Anti-Infective Agents Phase 4
17 Hormone Antagonists Phase 4
18 Antifungal Agents Phase 4
19 Cytochrome P-450 Enzyme Inhibitors Phase 4
20 Cytochrome P-450 CYP3A Inhibitors Phase 4
21 Dermatologic Agents Phase 4
22 Anti-Inflammatory Agents Phase 4
23 Calcineurin Inhibitors Phase 4
24 Immunosuppressive Agents Phase 4
25 Immunologic Factors Phase 4
26 Emollients Phase 4
27
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
28
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
29
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
31
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
32
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
33
Clobetasol Approved, Experimental, Investigational Phase 3 25122-46-7, 25122-41-2 2791 5311051 32798
34
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
35 Antineoplastic Agents, Hormonal Phase 3
36 Anti-Asthmatic Agents Phase 3
37 Neuroprotective Agents Phase 3
38 Betamethasone-17,21-dipropionate Phase 3
39
Betamethasone Valerate Phase 3 2152-44-5
40
Betamethasone sodium phosphate Phase 3
41
Betamethasone benzoate Phase 3
42 Antiemetics Phase 3
43 Respiratory System Agents Phase 3
44
Methylprednisolone Acetate Phase 3 584547
45 Gastrointestinal Agents Phase 3
46 Protective Agents Phase 3
47 glucocorticoids Phase 3
48
Azelaic acid Approved Phase 2 123-99-9 2266
49
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 17753757 6509979
50
Acetylcholine Approved, Investigational Phase 1 51-84-3 187

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
2 A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS Completed NCT00703846 Phase 4 Ketoconazole
3 Phase 4 Study of Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis Completed NCT01591070 Phase 4 Tacrolimus
4 A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis Completed NCT03567980 Phase 4 Crisaborole
5 A Double Blind, Placebo-Controlled, Pilot Study to Estimate the Efficacy and Tolerability of Twice Daily Promiseb Topical Cream in Pediatric Subjects With Cradle Cap (Seborrheic Dermatitis) Completed NCT01214434 Phase 4
6 Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis Unknown status NCT01011621 Phase 3 0.5% prednisolone acetate cream;0.1% betamethasone valerate cream
7 Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis Completed NCT00862654 Phase 3 clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week);clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week);clobetasol propionate shampoo (2/week);ketoconazole shampoo (2/week)
8 Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face Completed NCT02004860 Phase 3 Protopic (R);Mycoster (R)
9 A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis Completed NCT04973228 Phase 3 ARQ-154 - Active;ARQ-154 Vehicle
10 Efficacy and Safety of ASF 1057 Cream 0.5% in the Treatment of Seborrhoeic Dermatitis: A Phase III Randomised, Double-Blind, Vehicle and Placebo Controlled, Parallel Groups, Multi-Centre Trial. Completed NCT00565279 Phase 3 ASF1057
11 A Multicenter, Randomised Double Blind, Placebo Controlled Study of Efficacy, Safety and Tolerability of Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp. Completed NCT01137630 Phase 2, Phase 3 K40a;K40b;Placebo
12 A Multicenter, Randomised, Double Blind, Placebo-controlled Study of Efficacy, Safety, and Tolerability of Kaprolac® K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp Completed NCT01137331 Phase 3 K301;Placebo
13 A Phase 2, Randomized, Vehicle and Ketoconazole-Controlled, Evaluator-Blinded, Study to Explore the Efficacy, Pharmacodynamics and Safety of Omiganan 1.75% Topical Gel BID in Patients With Mild to Moderate Facial Seborrheic Dermatitis Unknown status NCT03688971 Phase 2 Omiganan;Ketoconazole;Placebo
14 A Double-Blind, Randomized, Vehicle-Controlled, Six-Week Exploratory Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Seborrheic Dermatitis of the Face Completed NCT00408330 Phase 2 Azelaic Acid 15% Gel;Inactive 15% gel base
15 A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis Completed NCT04091646 Phase 2 ARQ-154 foam 0.3%;ARQ-154 vehicle foam
16 A Randomized, Double-blind, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Seborrheic Dermatitis of the Face Completed NCT02749383 Phase 2 PAC-14028 cream 0.3%;PAC-14028 cream 1.0%;PAC-14028 cream vehicle
17 A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis Completed NCT01703793 Phase 2 Test Product 49778;Test Product 10156;Vehicle (placebo)
18 A 4 Week Randomized Double-blind Parallel Group Active Comparator Controlled Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis Completed NCT00403559 Phase 2 Elidel;Ketoconazole Cream
19 A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects With Seborrheic Dermatitis Completed NCT04445987 Phase 2 ARQ-154
20 The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial Completed NCT00991198 Phase 2 Topical oxygen;placebo
21 A 4-Week, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate the Potential of Topically Applied 0.75% (w/w) MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers Completed NCT01254162 Phase 2 MTC896 Gel
22 Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adults Recruiting NCT03830177 Phase 1, Phase 2 Natural Treatment
23 Double-blind, Randomized, Placebo Controlled Study Evaluating the Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis Withdrawn NCT01574872 Phase 2
24 Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Unknown status NCT00767546 Phase 1 Botulinum toxin
25 Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation Unknown status NCT01315951
26 Avaliação da eficácia de um Produto de Uso tópico Contendo Hidrocortisona no Tratamento de Dermatite seborréica na Face. Unknown status NCT01024374
27 Using the SpiderMass(TM) for in Vivo and Real Time Mass Spectrometry Analysis of Subject's Epidermis Suffering From Chronic Inflammatory Dermatosis Compared to Control Groups Unknown status NCT04472546
28 An Open-Label Study of the HairMax LaserComb(r) in the Treatment of Seborrheic Dermatitis of the Scalp. Completed NCT00830908
29 Comparison of Scalp Microbiota of the Patients With Psoriasis Vulgaris and Seborrheic Dermatitis Completed NCT03807453
30 Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis Completed NCT02656368
31 Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis Completed NCT03114111 Early Phase 1 aminolevulinic acid (ALA);Placebo
32 Neurobiology of the Scalp in Seborrheic Dermatitis Completed NCT02349854
33 Multicentric, Randomized, Double Blind Study Under Dermatological Control for Evaluation of the Antidandruff Maintenance Effect of One Shampoo (Reference 1144628 D) Versus Its Vehicle (Reference 1144781) During 8 Weeks After a Ketoconazole-based Antifungal Treatment During 4 Weeks in Adult Subjects (Male and Female) With Light to Moderate Seborrheic Dermatitis Completed NCT04057950
34 Seborrheic Dermatitis of the Scalp in Populations Practicing Less Frequent Hair Washing: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo Completed NCT01203189 ketoconazole 2% foam;ketoconazole 2% shampoo
35 Retrospective Study to Evaluate the Safety of Sebryl® and / or Sebryl Plus® in the Treatment of Seborrheic Dermatitis and Psoriasis of the Scalp in Routine Medical Practice. Completed NCT05105139
36 Study to Evaluate Physician Awareness and Knowledge of Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Monotherapies in Europe: an Observational Post-Authorisation Joint Safety Study (Safe-CAM) Completed NCT04925180 Cyproterone Acetate (Androcur, BAY94-8367)
37 Drug Utilization Study on the Prescribing Indications for Cyproterone Acetate and Ethinyl Estradiol in 5 European Countries Completed NCT02494297
38 Cleansing Device for the Treatment of Scalp and Hair Conditions Recruiting NCT05319444
39 Supporting Health Care Professionals in Hospital and Primary Care to Promote Adequate HIV Risk and Indicator Condition Driven Testing in Routine Care. Recruiting NCT05225493

Search NIH Clinical Center for Seborrheic Dermatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
chloroxine
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Colloid sulfur
Ketoconazole
Salicylic Acid
SALICYLIC ACID PWDR
selenium sulfide
Sulfacetamide
Sulfacetamide Sodium
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
zinc pyrithione

Cochrane evidence based reviews: dermatitis, seborrheic

Genetic Tests for Seborrheic Dermatitis

Genetic tests related to Seborrheic Dermatitis:

# Genetic test Affiliating Genes
1 Seborrheic Dermatitis 28

Anatomical Context for Seborrheic Dermatitis

Organs/tissues related to Seborrheic Dermatitis:

MalaCards : Skin, Ovary, Spinal Cord, Tongue, Pituitary, T Cells, Liver

Publications for Seborrheic Dermatitis

Articles related to Seborrheic Dermatitis:

(show top 50) (show all 2339)
# Title Authors PMID Year
1
[Effect on skin and hormonal hyperandrogenic manifestations of an oral estroprogestin association containing ethynilestradiol 30 mg and drospirenone 3 mg]. 53 62
18547986 2008
2
The effect of isotretinoin on biotinidase activity. 53 62
10325581 1999
3
Infantile spasms as the initial symptom of biotinidase deficiency. 53 62
8283357 1994
4
Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. 62
36093833 2022
5
The human pathobiont Malassezia furfur secreted protease Mfsap1 regulates cell dispersal and exacerbates skin inflammation. 62
36442106 2022
6
Sensitive Scalp: Diagnosis and Practical Management. 62
36470396 2022
7
Analysis of cutaneous bacterial microbiota of Thai patients with seborrheic dermatitis. 62
36076320 2022
8
An Up-to-Date Approach to the Management of Seborrheic Dermatitis. 62
36468970 2022
9
Heterologous expression and biochemical characterisation of the recombinant β-carbonic anhydrase (MpaCA) from the warm-blooded vertebrate pathogen malassezia pachydermatis. 62
34894958 2022
10
The global, regional, and national burden of seborrheic dermatitis: results and insights from the Global Burden of Disease 2019 Study. 62
36445473 2022
11
Sebaceous gland atrophy in seborrheic dermatitis of the scalp; a pilot study. 62
36222212 2022
12
Identification of Malassezia species isolated from some Malassezia associated skin diseases. 62
35700659 2022
13
Effectiveness of Sopoongsan for chronic upper body pruritus in patients with atopic or seborrheic dermatitis: A pilot study protocol for a randomized, double-blind, placebo-controlled, parallel trial. 62
36401407 2022
14
Evaluation of safety and effectiveness of gestrinone in the treatment of endometriosis: a systematic review and meta-analysis. 62
36434439 2022
15
Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review. 62
36434425 2022
16
[Occupational Dermatoses in Healthcare Workers during the COVID-19 Pandemic: A Narrative Review]. 62
35766244 2022
17
Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease. 62
36342675 2022
18
Establishment of a gene recombination method for a major human skin commensal fungus, Malassezia restricta, using Agrobacterium tumefaciens-mediated gene transfer system. 62
36413464 2022
19
Dissecting cellulitis of the scalp with typical clinical features: A retrospective cross-sectional study in a Department of Dermatology, Beijing, China. 62
35996875 2022
20
Seborrheic Dermatitis Is Related to Motor Symptoms in Parkinson's Disease. 62
36367060 2022
21
Is cutaneous microbiota a player in disease pathogenesis? Comparison of cutaneous microbiota in psoriasis and seborrheic dermatitis with scalp involvement. 62
35389020 2022
22
Masks trigger facial seborrheic dermatitis and psoriasis: evidence from a multicenter, case-control study during COVID-19 pandemic. 62
35829673 2022
23
Clinical observation and analysis of skin reactions caused by COVID-19 vaccination. 62
36190010 2022
24
Investigation of the relationship between inflammatory blood parameters and seborrheic dermatitis. 62
35403790 2022
25
Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know. 62
35032336 2022
26
Malignant syphilis in a young woman: A case report. 62
36217269 2022
27
β-1,4-Galactan suppresses lipid synthesis in sebaceous gland cells via TLR4. 62
36288613 2022
28
Botulinum Neurotoxin Type A Directly Affects Sebocytes and Modulates Oleic Acid-Induced Lipogenesis. 62
36287976 2022
29
Perialar intertrigo in children and adolescents: A multicenter prospective study of 41 cases. 62
35699273 2022
30
Influence of moisturizer containing licochalcone A, 1,2-decanediol, L-carnitine, and salicylic acid on facial skin lipidome among seborrhea participants. 62
36102580 2022
31
Therapeutic properties and molecular docking study of some phenolic compounds as anti-human lung cancer potential: A biochemical approach. 62
36106371 2022
32
A Meta-Analysis on the Effectiveness of Sertaconazole 2% Cream Compared with Other Topical Therapies for Seborrheic Dermatitis. 62
36143325 2022
33
Clinical study: Is seborrheic dermatitis associated with systemic inflammation? 62
34967482 2022
34
Sensitive Scalp: Diagnosis and Practical Management. 62
36174707 2022
35
Skin and gut microbiota dysbiosis in autoimmune and inflammatory skin diseases. 62
36149040 2022
36
Changing spectrum of hair and scalp disorders over the last decade in a tertiary medical centre. 62
36066315 2022
37
The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials. 62
36072203 2022
38
Mucocutaneous Manifestations of People Living with HIV in Current Antiretroviral Therapy Era. 62
35236269 2022
39
Complete blood cell count parameters and seborrheic dermatitis: Preanalytical and analytical considerations. 62
35943906 2022
40
Occupational Seborrheic Dermatitis in a Steel Worker. 62
35951435 2022
41
Evaluation of a new-formula shampoo containing 6% glycyrrhetinic acid complex for scalp seborrheic dermatitis: A pilot study. 62
34792270 2022
42
The change in the frequency and severity of facial dermatoses and complaints in healthcare workers during the COVID-19. 62
35509253 2022
43
Essential Oils as Potential Source of Anti-dandruff Agents: A Review. 62
34254910 2022
44
Effectiveness of FastFung agar in the isolation of Malassezia furfur from skin samples. 62
35506984 2022
45
Facial Dermatoses in Patients With Blepharitis: a Cross-sectional Prospective Analysis. 62
36159148 2022
46
Time-trends for eczema prevalences among children and adults from 1985 to 2015 in China: a systematic review. 62
35790959 2022
47
Examination of Cutaneous Changes Among Patients Following SARS-CoV-2 Infection. 62
36000106 2022
48
Exaggerated hyperkeratosis in a nursing home patient. 62
36387659 2022
49
Skin microbiome signatures associated with psoriasis and seborrheic dermatitis. 62
35638453 2022
50
Cutaneous manifestations of obesity in Turkish children: A comparative study. 62
35285075 2022

Variations for Seborrheic Dermatitis

Expression for Seborrheic Dermatitis

Search GEO for disease gene expression data for Seborrheic Dermatitis.

Pathways for Seborrheic Dermatitis

GO Terms for Seborrheic Dermatitis

Cellular components related to Seborrheic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.16 TNF DEFB4A CXCL8 CD1E CD1D CD1C
2 plasma membrane GO:0005886 10.02 ATRN CCR6 CD1A CD1C CD1D CD1E
3 plasma membrane GO:0005887 10.02 ATRN CCR6 CD1A CD1C CD1D CD1E
4 external side of plasma membrane GO:0009897 9.58 TNF CD4 CD207 CD1E CD1D CD1C

Biological processes related to Seborrheic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.03 CCR6 CD1A CD1B CD1C CD1D CD1E
2 positive regulation of T cell mediated cytotoxicity GO:0001916 9.96 CD1E CD1D CD1C CD1B CD1A
3 calcium-mediated signaling GO:0019722 9.92 TNF CXCL8 CD4 CCR6
4 immune system process GO:0002376 9.88 CD4 CD1E CD1D CD1C CD1B CD1A
5 T cell selection GO:0045058 9.67 CD4 CD1D
6 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.65 CD1E CD1D CD1C CD1B CD1A
7 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 9.32 CD1E CD1D CD1C CD1B CD1A

Molecular functions related to Seborrheic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopeptide binding GO:0071723 9.85 CD1E CD1D CD1C CD1B CD1A
2 exogenous lipid antigen binding GO:0030884 9.65 CD1E CD1D CD1C CD1B CD1A
3 endogenous lipid antigen binding GO:0030883 9.32 CD1E CD1D CD1C CD1B CD1A

Sources for Seborrheic Dermatitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....